Genetic polymorphism of CYP2D6 in the Japanese population

Pharmacogenetics

Volumn 9, Issue 5, 1999, Pages 601-605

  Chida, Michihiro ^a   Yokoi, Tsuyoshi ^a   Kosaka, Yasuyuki ^a   Chiba, Kan ^b   Nakamura, Hidefumi ^c   Ishizaki, Takashi ^d   Yokota, Jun ^e   Kinoshita, Moritoshi ^f   Sato, Kunio ^g   Inaba, Makoto ^h   Aoki, Yasuhiro ⁱ   Gonzalez, Frank J ^j   Kamataki, Tetsuya ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^d KUMAMOTO UNIVERSITY   (Japan)

^e NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^f OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^g GUNMA UNIVERSITY   (Japan)

^h CANCER CHEMOTHERAPY CENTER   (Japan)

ⁱ IWATE MEDICAL UNIVERSITY   (Japan)

^j NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

Cancer risk; CYP2D6*18; CYP2D6*3; CYP2D6*4; CYP2D6*5; Parkinson's disease; Population study

Indexed keywords

ARTICLE; CANCER; COLORECTAL CANCER; CONTROLLED STUDY; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; JAPAN; LUNG CANCER; MAJOR CLINICAL STUDY; PARKINSON DISEASE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ALLELES; BASE SEQUENCE; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP2D6; DNA PRIMERS; GENE FREQUENCY; HUMANS; JAPAN; MUTATION; NEOPLASMS; PARKINSON DISEASE; PHARMACOGENETICS; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH;

PARKINSONIA;

EID: 0032717824     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Armstrong M, Daly AK, Cholerton S, Bateman DN, Idle JR. Mutant debrisoquine genes in Parkinson's disease. Lancet 1992; 339:1017-1018.
2. Armstrong M, Fairbrother K, Idle JR, Daly AK. The cytochrome P450 CYP2D6 allelic variant CYP2D6 J and related polymorphism in a European population. Pharmacogenetics 1994; 4:73-81.
3. Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 1991; 8:545-558.
4. Broly F, Mare D, LoGuidice JM, Sabbagh N, Legrand M, Boone P, Meyer UA. A nonsense mutation in the cytochrome P450 CYP2D6 gene identified in a Caucasian with an enzyme deficiency. Human Genet 1995; 96:601-603.
5. Dahl ML, Johansson I, Porsmyr Palmertz M, Ingelman-Sundberg M, Sjöqvist F. Analysis of the CYP2D6 gene in relation to debrisoquine and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther 1992; 51:12-1 7.
6. Dahl ML, Yue QY, Roh HK, Johansson I, Säwe J, Sjöqvist F, Bertilsson L. Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects. Pharmacogenetics 1995; 5:159-164.
7. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ. et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996; 6:193-201.
8. Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/sparteine metabolism - clinical aspects. Pharmacol Ther 1990; 46:377-394.
9. Evans DAP, Mahgoub A, Sloan TP, Idle JR, Smith RL. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 1980; 17:102-105.
10. Evans WE, Relling MV, Rahman A, McLeod HL, Scott EP, Lin JS. Genetic basis for low prevalence of deficient CYP2D6 oxidative drug metabolism in black Americans. J Clin Invest 1993; 91:2150-2154.
11. Evert B, Griese EU, Eichelbaum M. A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine. Naunyn-Schmiedeberg's Arch Pharmacol 1994; 350:434-439.
12. Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Human Genet 1991; 48:943-950.
13. Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, Nebert DW, et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 1988; 331:442-446.
14. Gough AC, Miles JS, Spurr NK, Moss JE, Gaedigk A, Eichelbaum M, Wolf CR. Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature 1990; 347:773-776.
15. Heim M, Meyer UA. Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet 1990; 336:529-532.
16. Horai Y, Nakano M, Ishizaki T, Ishikawa K, Zhou HH, Zhou BJ, et al. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese vs. mainland Chinese. Clin Pharmacol Ther 1989; 46:198-207.
17. Ishizaki T, Eiehelbaum M. Horai Y, Hashimoto K, Chiba K, Dengler HJ. Evidence for polymorphic oxidation of sparteine in Japanese subjects. Br J Clin Pharmacol 1987; 23:482-485.
18. Johansson I, Yue QY, Dahl ML, Heim M, Säwe J, Bertilsson L, et al. Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine. Eur J Clin Pharmacol 1991; 40:553-556.
19. Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. J Biol Chem 1990; 265:17209-17214.
20. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet 1989; 45:889-904.
21. Kurth MC, Kurth JH. Variant cytochrome P450 CYP2D6 allelic frequencies in Parkinson's disease. Am J Med Genet 1993; 48:166-168.
22. Marez D, Sabbagh N, Legrand M, LoGuidice JM, Boone P, Broly F. A novel CYP2D6 allele with an abolished splice recognition site associated with the poor metabolizer phenotype. Pharmacogeneties 1995; 5:305-311.
23. Masimirembwa CM, Johansson I, Hasler JA, Ingelman-Sundberg M. Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean population. Pharmacogenetics 1993; 3:275-280.
24. Morgan MY, Reshef R, Shah RR, Oates NS, Smith RL, Sherlock S. Impaired oxidation of debrisoquine in patients with perhexline liver injury. Gut 1984; 25:1057-1064.
25. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985; 38:402-408.
26. Newton BW, Benson RC, McCorriston CC. Sparteine sulfate: a potent, capricious oxytocic. Am J Obstet Gynecol 1966; 94:234-241.
27. Rannug A, Alexandrie AK, Persson I, Ingelman-Sundberg M. Genetic polymorphism of cytochromes P450 1A1, 2D6 and 2E1: regulation and toxicological significance. J Occup Environ Med 1995; 37:25-36.
28. Relling MV, Cherrie J, Schell MJ, Petros WP, Meyer WH, Evans WE. Lower prevalence of the debrisoquine oxidative poor metaboliser phenotype in American blacks vs. white subjects. Clin Pharmacol Ther 1991; 50:308-313.
29. Sambrook J. Fritsch EE, Maniatis T. Molecular cloning: a laboratory manual. 2nd edn, New York: Cold Spring Harbor Laboratory Press; 1989 pp. 9-16-9-19.
30. Saxena R, Shaw GL, Relling MV, Frame JN, Moir DT, Fvans WF, et al. Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor melabolizer phenotype. Hum Mol Genet 1994; 3:923-926.
31. Skoda RC, Gonzalez FJ, Demierre A, Meyer UA. Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci USA 1988; 85:5240-5243.
32. Smith RL. Introduction. Human genetic variations in oxidative drug metabolism. Xenobiotica 1986; 16:361-365.
33. Smith CAD, Gough AC, Leigh PN, Summers BA, Harding AE, Maranganore DM, et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 1992; 339:1375-1377.
34. Sohn DR, Shin SG, Park CW, Kusaka M, Chiba K, Ishizaki T. Metoprolol oxidation polymorphism in a Korean population: Comparison with native Japanese and Chinese populations, Br J Clin Pharmacol 1991; 32:504-507
35. Steiner E, Iselius L, Alván G. Lindsten J, Sjöqvist F. A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin. Clin Pharmacol Ther 1985; 38:394-401.
36. Tucker GT. Clinical implications of genetic polymorphism in drug metabolism. J Pharm Pharmacol 1994; 46:417-424.
37. Tsuneoka Y, Matsuo Y, Iwahashi K, Takeuchi H, Ichikawa Y. A novel cytochrome P-450IID6 mutant gene associated with Parkinson's disease. J Biochem 1993; 114:263-266.
38. Wang SL, Haung J, Lai MD, Liu BH, Lai ML. Molecular basis of genetic variation in debrisoquine hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther 1993; 53:410-418.
39. Yokoi T, Kosaka Y, Chida M, Chiba K, Nakamura H, Ishizaki T, et al. A new CYP2D6 allele with a nine base insertion in exon 9 in a Japanese population associated with poor metabolizer phenotype. Pharmacogenetics 1996; 6:395-401.
40. Yokota H, Tamura S, Furuya H, Kimura S, Watanabe M, Kanazawa I, et al. Evidence for a new variant CYP2D6 allele CYP2D6 J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Pharmacogenetics 1993; 3:256-263b